BAJAJ BROKING
Mankind Pharma signed a licensing deal with Innovent Biologics to introduce Sintilimab, an anti-cancer PD-1 immunotherapy, in India. Estimated market size is ₹8,000 crore. Mankind Pharma share price remains stable amid this expansion into oncology.
Mankind Pharma has announced a licensing agreement with Chinese pharmaceutical giant Innovent Biologics to introduce Sintilimab, a cutting-edge PD-1 immunotherapy, in India. The partnership grants Mankind exclusive rights to register, import, market, sell, and distribute the drug, while Innovent oversees manufacturing and supply. This development signifies Mankind’s strategic focus on strengthening its oncology portfolio in the ₹8,000-crore Indian oncology market.
Also read: Jubilant FoodWorks Partners with Coca-Cola for Beverage Supply
Drug Name: Sintilimab (Marketed as TYVYT in China).
Mechanism: Blocks PD-1/PD-L1 pathway to enhance T-cell activity against cancer cells.
Launch Timeline: Expected in three years post Phase III trials and regulatory approvals.
Market Size: Indian oncology market valued at ₹8,000 crore.
Mankind Pharma Share Price: Stable amid announcement.
Also read: IndusInd Bank to Sell ₹1,573-Crore MFI Retail Loan Pool in Auction
Sintilimab, developed by Innovent Biologics in collaboration with Eli Lilly, is a monoclonal antibody targeting multiple cancer types. It is approved for eight indications in China, including:
Cancer Type | Indications |
Non-Small Cell Lung Cancer | First-Line Treatment |
Liver Cancer | Advanced Stages |
Gastric Cancer | First-Line Therapy |
Esophageal Cancer | Recurrence or Advanced Cases |
Endometrial Cancer | Advanced Stages |
Hodgkin’s Lymphoma | Second-Line Therapy |
Mankind’s entry into oncology began in 2023 with the acquisition of Panacea Biotec for ₹1,872 crore. The addition of Sintilimab aligns with the company's focus on biologics and immunotherapies as future cancer treatments. The drug's competitive pricing is expected to enhance accessibility in the Indian market.
Mankind Pharma share price remains steady following the announcement, reflecting investor confidence in its strategic expansion. With over 16,000 personnel and 13,000 stockists, Mankind’s robust distribution network is well-positioned to support the launch.
Mankind Pharma’s licensing agreement with Innovent Biologics marks a significant step towards transforming cancer care in India. By introducing Sintilimab, the company is poised to make advanced immunotherapy accessible to Indian patients while solidifying its position in the oncology market.
Also read: Gensol Engineering Secures ₹897-Crore Contract for NTPC REL Solar Projects
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Gold Price in India | Gold Rises 0.7% to $2,653.70; Silver Adds 0.4% to $30.42
27 Dec, 2024 | 40 Min. read
IndusInd Bank to Sell ₹1,573-Crore MFI Retail Loan Pool in Auction
27 Dec, 2024 | 2 Min. read
Mankind Pharma Signs Licensing Pact with Innovent for Sintilimab
27 Dec, 2024 | 2 Min. read
Share Market Today | Gift Nifty Hints At Positive Start For Indian Markets, 23,500-24,200
27 Dec, 2024 | 4 Min. read
Jubilant FoodWorks Partners with Coca-Cola for Beverage Supply
27 Dec, 2024 | 2 Min. read
Gensol Engineering Secures ₹897-Crore Contract for NTPC REL Solar Projects
27 Dec, 2024 | 2 Min. read
How to Apply for Indo Farm Equipment IPO & Check Allotment Status?
27 Dec, 2024 | 1 Min. read
How to Apply for Citichem India IPO & Check Allotment Status?
27 Dec, 2024 | 1 Min. read
Know the Objective & Analysis of Citichem India IPO
27 Dec, 2024 | 3 Min. read
Know the Objective & Analysis of Indo Farm Equipment IPO
27 Dec, 2024 | 3 Min. read
Pips in Forex Trading: Meaning, Examples & Calculate
27 Dec, 2024 | 1 Min. read
Trailing Stop Loss: Overview, Key Features & Examples
27 Dec, 2024 | 4 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading